English | 简体中文 | 繁體中文 | 한국어 | 日本語
Friday, 24 September 2021, 07:00 HKT/SGT
Share:
        

Source: ACROMEC Engineers / Life Sciences Incubator
ACROMEC's associate Life Science Incubator launches Co-working Labspace
Serving start-ups in MedTech, Biotech, Biopharma and FoodTech, the Incubator aims to become a vibrant centre of entrepreneurship, technology and science.

SINGAPORE, Sept 24, 2021 - (ACN Newswire) - ACROMEC Limited (ACROMEC; SGX: 43F), a specialist engineering services provider, announced that subsidiary ACROMEC Engineers Pte Ltd (ACROMEC Engineers) through joint-venture associate Life Science Incubator Pte Ltd, has launched the first Life Science Incubator co-working laboratory space, with a ceremony on location at the German Centre, International Business Plaza, Singapore.


The ceremony was attended by Mr Alvin Tan, Minister of State, Ministry of Culture, Community and Youth and Ministry of Trade & Industry and others from the Economic Development Board, Enterprise Singapore, SGInnovate, A*STAR, NTUitiv and NUS accelerator. Members of Life Science Incubator's current network of some 20 industry partners, including Merck, also attended the event.

Serving early-stage bio and pharma start-ups, companies and entrepreneurs in the MedTech, Biotech, Biopharma and FoodTech sectors, Life Science Incubator will provide flexible co-working laboratory spaces for research and development. With access to communal state-of-the-art technologies and facilities, start-ups will be able to fully focus on innovation and talent in science without having to think about hefty infrastructure capital.

Said Niamh Madden, General Manager of Life Science Incubator, "Today marks the start of our exciting journey at the Life Science Incubator. We look forward to supporting science and technology start-ups and being an integral launchpad for their endeavours. With our strong network of partner companies, we are confident that the incubator will become a vibrant centre of entrepreneurship, technology and science."

Said Mr Lim Say Chin, Executive Chairman and Managing Director of ACROMEC, "The successful completion and launch of the Life Science Incubator attests to ACROMEC's track record and success as a specialist engineering provider for controlled environments. We are excited to be a part of this vibrant ecosystem and will continue to serve companies and start-ups in the life science, biotech, healthcare, and research sectors."

In July, the Group announced that wholly-owned subsidiary ACROMEC Engineers had entered into a joint-venture agreement with strategic partner Tako Ventures to build, own, and operate JVCo and co-working laboratory facilities. JVCo is 30% owned by the Group through ACROMEC Engineers, while Tako Ventures holds the remaining 70% stake, managing JVCo and the Life Science Incubator.

ACROMEC Engineers undertook the design, construction, and fitting-out works for the 600 square meter Life Science Incubator's co-working lab facilities, which includes 8 suites, 51 lab benches, and 1 operating theatre.

About ACROMEC Limited
SGX Catalyst-listed ACROMEC (SGX: 43F) is an established specialist engineering services provider with more than 20 years of acquiring expertise in the design and construction of facilities requiring controlled environments, such as laboratories, medical and sterile facilities and cleanrooms. Amongst its customers, ACROMEC counts hospitals & medical centres, government agencies, educational institutions, research & development companies and multinational units, pharmaceutical, semiconductor manufacturing and engineering companies. For more information, visit www.acromec.com.

ACROMEC share information through SGX (43F), Bloomberg (ACRO.SG) and ThomsonReuters (ACRO.SI).

Analyst & Media contact:
ACROMEC Limited
Mr Jerry Tan, CFO
E: jerry.tan@acromec.com

Waterbrooks Consultants Pte Ltd
Mr Wayne Koo / Ms Raihana
T: +65 6958 8002 / +65 9338 8166
E: wayne.koo@waterbrooks.com.sg / raihana@waterbrooks.com.sg


Topic: Press release summary
Source: ACROMEC Engineers / Life Sciences Incubator

Sectors: Healthcare & Pharm, PE, VC & Alternatives, Construct, Engineering, Startups
https://www.acnnewswire.com
From the Asia Corporate News Network


Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.

 

Latest Press Releases
A New Benchmark for Specialized Technology Stocks in Hong Kong! CiDi's Listing Marks a New Chapter in Commercial Intelligent Driving  
Dec 19, 2025 10:30 HKT/SGT
Air T, Inc. Announces Closing of Regional Express Acquisition  
Dec 19, 2025 06:10 HKT/SGT
MHI Participates in Demonstration Testing of Vehicle-Infrastructure Integration System for Autonomous Buses in Shimotsuke City  
Friday, December 19, 2025 2:24:00 AM
NEC and emaratech Collaborate on Biometric Smart Gates Supporting UAE Airport Operations  
Friday, December 19, 2025 2:06:00 AM
Fujitsu to showcase mobility and physical AI tech at CES 2026  
Friday, December 19, 2025 1:42:00 AM
Kirin and Fujitsu elucidate a novel gut-brain axis mechanism of citicoline for the first time worldwide through AI-based analysis and experimental validation leveraging drug discovery DX technology  
Friday, December 19, 2025 1:06:00 AM
TANAKA PRECIOUS METAL GROUP and TANAKA MIRAI Lab. Released Their Fourth Collaborative Musical Work with Sound Wellness Lab (Della): "Precious Metal Orchestra - A Musical Voyage through the Sound of Precious Metals for Christmas" now available for streaming.  
Thursday, December 18, 2025 9:00:00 PM
Focus Graphite Announces Final Results From 2022 Drill Program at Lac Tetepisca; West Limb Extends Mineralized Strike to 8 KM  
Dec 18, 2025 18:09 HKT/SGT
Spritzer MerryLand Returns This Year-End, Bringing Magical Festive Cheer to Taiping  
Dec 18, 2025 17:44 HKT/SGT
PropertyGuru Asia Real Estate Summit spotlights PropertyGuru Week 2025 with conversations on 'Trusted Marketplaces and Thriving Communities'  
Thursday, December 18, 2025 9:00:00 AM
More Press release >>
 Events:
More events >>
Copyright © 2025 ACN Newswire - Asia Corporate News Network
Home | About us | Services | Partners | Events | Login | Contact us | Cookies Policy | Privacy Policy | Disclaimer | Terms of Use | RSS
US: +1 214 890 4418 | China: +86 181 2376 3721 | Hong Kong: +852 8192 4922 | Singapore: +65 6549 7068 | Tokyo: +81 3 6859 8575